126 related articles for article (PubMed ID: 31496508)
1. Topiroxostat influences circulating lipid concentrations in hyperuricemic patients
.
Tohyo S
Int J Clin Pharmacol Ther; 2019 Nov; 57(11):567-570. PubMed ID: 31496508
[TBL] [Abstract][Full Text] [Related]
2. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
3. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
Horino T; Hatakeyama Y; Ichii O; Matsumoto T; Shimamura Y; Inoue K; Terada Y; Okuhara Y
Clin Exp Nephrol; 2018 Apr; 22(2):337-345. PubMed ID: 28752287
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Hosoya T; Sasaki T; Ohashi T
Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
[TBL] [Abstract][Full Text] [Related]
6. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
7. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
[TBL] [Abstract][Full Text] [Related]
8. Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Sezai A; Obata K; Abe K; Kanno S; Sekino H
Circ J; 2017 Oct; 81(11):1707-1712. PubMed ID: 28603225
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
Ishikawa T; Maeda T; Hashimoto T; Nakagawa T; Ichikawa K; Sato Y; Kanno Y
Clin Drug Investig; 2020 Sep; 40(9):847-859. PubMed ID: 32621143
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.
Tanaka A; Nakamura T; Sato E; Node K
Drugs R D; 2017 Mar; 17(1):97-101. PubMed ID: 28074335
[TBL] [Abstract][Full Text] [Related]
11. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
[TBL] [Abstract][Full Text] [Related]
12. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Hosoya T; Ohno I; Nomura S; Hisatome I; Uchida S; Fujimori S; Yamamoto T; Hara S
Clin Exp Nephrol; 2014 Dec; 18(6):876-84. PubMed ID: 24448692
[TBL] [Abstract][Full Text] [Related]
13. The effects of topiroxostat on vascular function in patients with hyperuricemia.
Higa S; Shima D; Tomitani N; Fujimoto Y; Kario K
J Clin Hypertens (Greenwich); 2019 Nov; 21(11):1713-1720. PubMed ID: 31556223
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.
Hosoya T; Ishikawa T; Ogawa Y; Sakamoto R; Ohashi T
Clin Drug Investig; 2018 Dec; 38(12):1135-1143. PubMed ID: 30219951
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
Mitsuboshi S; Yamada H; Nagai K; Okajima H
Biol Pharm Bull; 2017; 40(9):1463-1467. PubMed ID: 28867729
[TBL] [Abstract][Full Text] [Related]
16. Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study.
Wakita M; Asai K; Kubota Y; Koen M; Shimizu W
J Nippon Med Sch; 2021 Nov; 88(5):423-431. PubMed ID: 33455978
[TBL] [Abstract][Full Text] [Related]
17. Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study.
Rozza F; Trimarco V; Izzo R; Grassi D; Ferri C
High Blood Press Cardiovasc Prev; 2016 Dec; 23(4):381-386. PubMed ID: 27644242
[TBL] [Abstract][Full Text] [Related]
18. The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis.
Nagaoka Y; Tanaka Y; Yoshimoto H; Suzuki R; Ryu K; Ueda M; Akiyama M; Nagai M; Miyaoka Y; Kanda E; Iwai S; Nagaoka M; Kanno Y
Hemodial Int; 2018 Jul; 22(3):388-393. PubMed ID: 29227568
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Kario K; Nishizawa M; Kiuchi M; Kiyosue A; Tomita F; Ohtani H; Abe Y; Kuga H; Miyazaki S; Kasai T; Hongou M; Yasu T; Kuramochi J; Fukumoto Y; Hoshide S; Hisatome I
J Clin Hypertens (Greenwich); 2021 Feb; 23(2):334-344. PubMed ID: 33400348
[TBL] [Abstract][Full Text] [Related]
20. Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study).
Kato S; Ando M; Mizukoshi T; Nagata T; Katsuno T; Kosugi T; Tsuboi N; Maruyama S
Nagoya J Med Sci; 2016 May; 78(2):135-42. PubMed ID: 27303100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
